The miR-221-5p/RAD18/RAD51 Axis Regulates DNA Damage Tolerance and Homologous Recombination to Drive Platinum Resistance in Ovarian Cancer
This study reveals that miR-221-5p acts as a tumor suppressor in epithelial ovarian cancer by directly targeting and downregulating RAD18 and RAD51, thereby inhibiting DNA damage tolerance and homologous recombination to overcome platinum resistance and sensitize tumors to chemotherapy and PARP inhibition.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Every year, hundreds of thousands of women worldwide are diagnosed with ovarian cancer, a disease that often strikes silently and is frequently found only after it has spread. For many, the initial treatment works well: surgeons remove as much of the tumor as possible, and powerful drugs based on platinum kill off the remaining cancer cells. Yet, for a majority of these patients, the cancer eventually returns. When it does, it is often because the tumor has learned to ignore the drugs, a phenomenon known as chemoresistance. The key to this survival lies in how cancer cells handle damage. Platinum drugs work by snapping the DNA strands inside a cell, essentially breaking the instruction manual the cell needs to survive. To stay alive, cancer cells have developed sophisticated repair crews that can fix these breaks or bypass the damage to keep copying their DNA. If scientists can understand how these repair crews are switched on, they might find a way to turn them off, leaving the cancer vulnerable to the very drugs that once failed.
In a new study, researchers at Texas Tech University Health Sciences Center and Indiana University School of Medicine have uncovered a specific switch that controls these repair crews in ovarian cancer. They focused on a tiny molecule called miR-221-5p. While scientists have long known that a related molecule often helps cancer grow, this team discovered that miR-221-5p actually acts as a brake, stopping the cancer from repairing itself. In healthy cells, this molecule is present, but in aggressive ovarian tumors, it disappears. Without this brake, two critical repair proteins, RAD18 and RAD51, become overactive. RAD18 helps cells copy their DNA even when it is damaged, while RAD51 acts as a master mechanic that fixes broken DNA strands. When these two proteins are allowed to run unchecked, the cancer cells can repair the damage caused by platinum drugs and survive the treatment.
The researchers began by looking at data from thousands of ovarian cancer patients and found a clear pattern: tumors with high levels of RAD18 and RAD51 were linked to shorter survival times and a higher chance of the cancer returning. They also noticed that in these same aggressive tumors, the levels of miR-221-5p were dangerously low. To test if this missing molecule was the cause, the team turned to laboratory models. They took cancer cells that had become resistant to platinum drugs and reintroduced miR-221-5p. The result was immediate and dramatic. As soon as the molecule was restored, the levels of the two repair proteins dropped. The cancer cells lost their ability to fix the damage. When these cells were exposed to platinum drugs again, they could no longer repair the broken DNA and died in much larger numbers than before.
To be certain that miR-221-5p was directly controlling these repair proteins, the team performed a series of precise experiments. They showed that miR-221-5p physically attaches to the instructions for making RAD18 and RAD51, effectively blocking the cell from producing them. When they blocked miR-221-5p in sensitive cells, the repair proteins surged, and the cells became resistant to treatment. Conversely, when they added the molecule to resistant cells, the repair proteins vanished, and the cells became sensitive again. This confirmed that the loss of miR-221-5p is a primary driver of drug resistance, acting as a master switch that turns on the cancer's survival mechanisms.
The study did not stop at simple cell cultures. The researchers grew three-dimensional clusters of cancer cells taken directly from patients, creating tiny models that behave more like real tumors. In these patient-derived models, restoring miR-221-5p also slowed down growth and reduced the cells' ability to invade surrounding tissues. To see if this would work in a living system, they implanted human ovarian cancer cells into mice. The mice that received cells with restored miR-221-5p developed significantly smaller tumors compared to those that received normal cancer cells. Inside these smaller tumors, the researchers found low levels of the repair proteins and fewer signs of cell division, proving that the molecule was suppressing the cancer's growth in a living body.
Perhaps most importantly, the researchers found that this approach could make the cancer vulnerable to other treatments as well. By disabling the repair crews, the cells became much more sensitive to a class of drugs called PARP inhibitors, which are designed to kill cells that cannot repair their DNA. This suggests that restoring miR-221-5p could turn a resistant tumor into one that is easily destroyed by existing therapies. The team also observed that this process did not simply stop the cell cycle or freeze the cells in place; instead, it specifically targeted the machinery used to fix DNA damage, leaving the cells unable to recover from the assault of chemotherapy.
While the results are promising, the researchers are careful to note that this work was conducted in laboratory settings and animal models. The next step will be to see if these findings hold true in larger groups of human patients and to figure out how to safely deliver this molecule to tumors in the body. Nevertheless, the study provides a clear map of a previously unknown pathway that drives drug resistance. It reveals that the disappearance of a single, tiny molecule can unleash a powerful repair system that saves cancer cells from death. By understanding this mechanism, scientists may be able to develop new strategies to rearm the immune system or drugs, ensuring that the cancer cells remain vulnerable to the treatments meant to cure them.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.